Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Ogivri
Generic Name
Trastuzumab-dkst
Active Ingredient
TrastuzumabCategory
Endoglycosidase [EPC]
Variants
3
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Ogivri, you must consult a qualified healthcare professional.
Detailed information about Ogivri
Trastuzumab is a recombinant DNA-derived humanized monoclonal antibody and HER2/neu receptor antagonist used primarily in the treatment of HER2-overexpressing breast and gastric cancers.
Dosage for Trastuzumab is highly individualized and is typically calculated based on the patient's body weight (mg/kg). Your oncologist (cancer doctor) will determine the exact schedule, which usually follows a 'loading dose' followed by 'maintenance doses.'
There are two primary schedules used in the adjuvant setting:
The safety and effectiveness of Trastuzumab in pediatric patients (children and adolescents under 18 years of age) have not been established. Clinical trials for the primary indications (breast and gastric cancer) are conducted in adult populations. Therefore, Trastuzumab is not currently approved for pediatric use.
Formal studies of Trastuzumab in patients with renal (kidney) impairment have not been conducted. However, because monoclonal antibodies are not primarily cleared by the kidneys, dosage adjustments are generally not required for patients with mild to moderate renal insufficiency. Caution is advised in patients with severe renal impairment.
No formal studies have been conducted in patients with hepatic (liver) impairment. As Trastuzumab is metabolized via general protein degradation rather than hepatic enzymes (like CYP450), liver function typically does not dictate the starting dose. However, liver function is monitored throughout therapy to ensure overall patient health.
In clinical trials, the risk of cardiac toxicity (heart problems) was found to be higher in patients over the age of 65. While the dosage remains the same based on weight, elderly patients require more frequent monitoring of their heart function (LVEF assessments).
Trastuzumab is a specialized medication that must be administered by a healthcare professional in a clinical setting (hospital or infusion center) equipped to handle potential infusion reactions.
If you miss an appointment for your Trastuzumab infusion, contact your oncologist immediately to reschedule. If the missed dose is delayed by one week or less, the maintenance dose (2 mg/kg for weekly or 6 mg/kg for three-weekly) should be given as soon as possible. If the dose is delayed by more than one week, a new loading dose (4 mg/kg for weekly or 8 mg/kg for three-weekly) may be required to quickly bring the drug levels back to the therapeutic range.
There is no specific antidote for a Trastuzumab overdose. In clinical trials, single doses up to 500 mg have been administered without reaching a 'maximum tolerated dose.' However, an overdose could potentially increase the risk of severe side effects, particularly cardiac toxicity or severe infusion reactions. If an overdose is suspected, the patient should be closely monitored for signs of heart failure or respiratory distress.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to adjust your schedule without medical guidance, as this could reduce the effectiveness of the treatment.
Most patients receiving Trastuzumab will experience some side effects. Many of these are manageable and decrease over time. Common side effects include:
Trastuzumab is a potent biological therapy that requires careful clinical oversight. It is not a traditional chemotherapy but a targeted antibody. Patients must be aware that while it is highly effective, it carries risks that necessitate frequent medical check-ups and laboratory testing. It is vital to disclose your entire medical history, especially any history of heart disease, high blood pressure, or lung conditions, to your oncologist before beginning treatment.
As mandated by the FDA, Trastuzumab carries the following boxed warnings:
There are no drugs that are strictly 'contraindicated' in the sense of causing an immediate chemical incompatibility in the body, but there are combinations that are avoided due to extreme toxicity risk:
Trastuzumab should never be used in the following circumstances:
These are conditions where the doctor must carefully weigh the risk of treatment against the potential benefit:
Trastuzumab is associated with significant risks during pregnancy. It is classified as having high embryo-fetal toxicity.
Trastuzumab is a humanized IgG1 kappa monoclonal antibody that binds with high affinity (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor 2 (HER2). The HER2 gene (also known as ERBB2) encodes a transmembrane receptor tyrosine kinase. When Trastuzumab binds to this receptor, it prevents the homodimerization and heterodimerization of HER2 with other HER receptors (like HER3). This blocking action inhibits the downstream signaling of the PI3K/Akt pathway, which is responsible for cell survival, and the MAPK pathway, which drives cell proliferation. Furthermore, the Fc portion of the Trastuzumab antibody recruits Natural Killer (NK) cells to the tumor site, inducing Antibody-Dependent Cellular Cytotoxicity (ADCC).
The pharmacodynamics of Trastuzumab are centered on its ability to arrest the cell cycle in the G1 phase. It also reduces the expression of vascular endothelial growth factor (VEGF), which inhibits the tumor's ability to grow new blood vessels. There is a clear dose-response relationship; maintaining serum trough concentrations above 20 mcg/mL is generally associated with optimal therapeutic outcomes in metastatic breast cancer. Tolerance (the drug becoming less effective over time) can occur if the cancer cells develop alternative signaling pathways to bypass the blocked HER2 receptor.
Common questions about Ogivri
Trastuzumab is primarily used to treat cancers that are 'HER2-positive,' meaning the cancer cells have too much of a protein called HER2. It is FDA-approved for the adjuvant (post-surgery) and metastatic treatment of HER2-positive breast cancer. Additionally, it is used to treat metastatic gastric (stomach) cancer and gastroesophageal junction cancer. By targeting the HER2 protein, it helps slow or stop the growth of these aggressive cancer cells. Your doctor will perform a specific test on your tumor tissue to confirm it is HER2-positive before prescribing this medication.
The most common side effects include fever, chills, nausea, and headache, which often occur as part of an 'infusion reaction' during the first dose. Many patients also experience fatigue, diarrhea, and a persistent cough or cold-like symptoms. Muscle and joint pain are also frequently reported throughout the treatment course. While these are common, the most serious concern is heart damage, which is why heart function is monitored regularly. Most mild side effects can be managed with over-the-counter medications recommended by your oncology team.
There is no direct chemical interaction between Trastuzumab and alcohol that would make the drug less effective. However, alcohol can strain the liver and dehydrate the body, which may worsen side effects like fatigue and nausea. Since Trastuzumab can also affect the heart, and excessive alcohol is toxic to heart tissue, moderation is key. It is always best to discuss your alcohol consumption with your doctor to ensure it doesn't interfere with your overall recovery. Staying well-hydrated with water is a priority during cancer therapy.
No, Trastuzumab is not considered safe during pregnancy and carries a boxed warning for embryo-fetal toxicity. It can cause a dangerous decrease in amniotic fluid (oligohydramnios), which is essential for the baby's lung and kidney development. This can lead to birth defects or even fetal death. Women who can become pregnant must have a negative pregnancy test before starting the drug and use effective birth control during treatment. This protection must continue for at least 7 months after the final dose because the drug stays in the body for a long time.
Trastuzumab begins working at the cellular level immediately after the first infusion, but its effects on the tumor are not visible right away. In the adjuvant setting (after surgery), it works 'silently' to kill any remaining microscopic cancer cells to prevent recurrence. In metastatic cancer, doctors typically evaluate the drug's effectiveness using imaging scans (like CT or PET scans) every 2 to 3 months. Some patients may see a reduction in tumor size or a stabilization of their disease within the first few cycles of treatment. The total duration of treatment is often one year for early-stage cancer.
While you can technically stop the infusions at any time without experiencing physical withdrawal symptoms, doing so can have serious consequences for your cancer treatment. In early-stage breast cancer, completing the full year of therapy is crucial for reducing the risk of the cancer coming back. In metastatic disease, stopping Trastuzumab may allow the cancer to begin growing again. If you are experiencing difficult side effects, talk to your doctor about managing them rather than stopping the drug abruptly. Any decision to discontinue should be made in consultation with your oncology team.
If you miss an appointment for your infusion, call your oncology clinic immediately to reschedule. The timing of Trastuzumab is important to maintain a steady level of the drug in your bloodstream. If the delay is only a few days, your doctor will likely give you the standard maintenance dose. However, if more than a week has passed since your scheduled dose, you may need to receive a higher 'loading dose' again to get back on track. Regular adherence to the schedule provides the best chance for a successful outcome.
Trastuzumab itself is not typically associated with significant weight gain, but it can cause fluid retention (edema), which might make you feel bloated or see a higher number on the scale. However, sudden or rapid weight gain (such as 5 pounds in a day or two) can be a sign of congestive heart failure, a serious side effect of the drug. If you notice swelling in your ankles or legs along with weight gain, you must contact your doctor immediately. Some patients may also gain weight due to other medications given alongside Trastuzumab, such as steroids.
Trastuzumab is frequently taken with other medications, including chemotherapy drugs like paclitaxel or docetaxel, and other targeted therapies like pertuzumab. However, it can interact dangerously with anthracyclines (like doxorubicin), significantly increasing the risk of heart damage. You must provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking. Your oncology team will carefully coordinate your treatment plan to avoid harmful interactions. Always check with your pharmacist before starting any new medication during your treatment year.
Trastuzumab is a biological drug, so it does not have 'generics' in the traditional sense, but it does have 'biosimilars.' Biosimilars are highly similar versions of the original drug (Herceptin) that have been FDA-approved to be just as safe and effective. Several biosimilars, such as Ogivri, Kanjinti, and Trazimera, are currently available and may be used depending on your insurance coverage and hospital pharmacy. These biosimilars work in the exact same way as the original brand-name drug and target the same HER2 receptors on cancer cells.
Other drugs with the same active ingredient (Trastuzumab)
> Warning: Stop taking Trastuzumab and call your doctor or seek emergency care immediately if you experience any of the following:
The most significant long-term concern with Trastuzumab is its effect on the heart. While many patients see an improvement in heart function after stopping the drug, some may develop permanent cardiomyopathy (weakened heart muscle). Patients who have received anthracyclines (like doxorubicin) in the past are at a higher risk for these long-term cardiac issues. Regular heart monitoring (every 3 months) is typically required for at least a year following the completion of therapy.
The FDA has issued several 'Black Box Warnings' for Trastuzumab, which are the most serious warnings used for prescription drugs:
Report any unusual symptoms or changes in your health to your healthcare provider immediately. Early detection of side effects is crucial for successful management.
While most infusion reactions are mild, true anaphylaxis can occur. Patients with a known hypersensitivity to Trastuzumab, Chinese Hamster Ovary (CHO) cell proteins, or any component of the formulation should not receive the drug. If a severe reaction occurs, the infusion must be stopped immediately and emergency medications (like epinephrine and steroids) administered.
The risk of heart failure is cumulative. This means the risk may increase the longer you are on the drug or if you have other risk factors like uncontrolled high blood pressure. Your doctor may pause or permanently stop Trastuzumab if your LVEF drops by a certain percentage (usually a drop of 10% or more from baseline to a level below 50%).
Patients who are experiencing shortness of breath at rest due to complications of advanced cancer or other comorbidities may be at increased risk of fatal infusion reactions. These patients should be treated with extreme caution.
To ensure safety, your healthcare team will perform the following:
Trastuzumab generally does not cause significant impairment of the ability to drive or operate machinery. However, because it can cause dizziness or fatigue in some patients, you should wait to see how the medication affects you before engaging in these activities.
There is no known direct interaction between alcohol and Trastuzumab. However, alcohol can cause dehydration and may worsen certain side effects like nausea or fatigue. It is best to limit alcohol consumption during cancer treatment to support overall liver and heart health.
Trastuzumab does not cause physical dependence, and there is no 'withdrawal syndrome' associated with stopping it. However, stopping the drug prematurely in the adjuvant setting may increase the risk of cancer recurrence. In the metastatic setting, stopping the drug may allow the cancer to grow or spread. Always discuss the risks and benefits of discontinuation with your oncologist.
> Important: Discuss all your medical conditions, including any history of heart, lung, or kidney disease, with your healthcare provider before starting Trastuzumab.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. This includes over-the-counter vitamins and 'natural' remedies, as they can impact your overall treatment safety.
Patients who have had reactions to other monoclonal antibodies (such as Rituximab or Pertuzumab) may be at a slightly higher risk for a reaction to Trastuzumab, although they are different molecules. There is no direct cross-reactivity documented, but the 'humanized' nature of these antibodies means the body's immune system is already primed to recognize similar protein structures. Always inform your nurse if you have reacted to any 'mab' (monoclonal antibody) drug in the past.
> Important: Your healthcare provider will evaluate your complete medical history, including heart and lung function tests, before prescribing Trastuzumab to ensure it is safe for you.
It is not known whether Trastuzumab is excreted in human breast milk. However, because human IgG (the type of protein Trastuzumab is) is secreted in milk and there is a potential for serious adverse reactions in the nursing infant, women are advised to discontinue breastfeeding during treatment and for 7 months after the last dose. The long half-life of the drug means it remains in the body long after the final infusion.
Trastuzumab is not approved for use in children. The conditions it treats (HER2+ breast and gastric cancer) are almost exclusively adult diseases. There is no data on how this drug affects growth, development, or the immature immune systems of children. If a pediatric patient has a rare HER2-positive tumor, treatment would only occur within the context of a highly specialized clinical trial.
Patients aged 65 and older are at a significantly higher risk of developing Trastuzumab-induced heart failure compared to younger patients. In clinical trials, the risk of a significant drop in LVEF was nearly double in the elderly population. While the drug is still used in this age group because of its life-saving potential, cardiac monitoring is performed with even greater frequency and caution. There are no specific dosage changes required based solely on age, but the patient's overall 'frailty' and existing heart health are key factors.
No specific studies have been conducted in patients with kidney disease. However, because Trastuzumab is a large protein, it is not filtered by the kidneys in the same way small drugs are. Pharmacokinetic modeling suggests that mild to moderate renal impairment does not significantly change the drug's levels in the blood. No dose adjustment is typically recommended for these patients.
Trastuzumab has not been studied in patients with significant liver disease. Since the drug is broken down by general cellular processes rather than the liver's metabolic enzymes, it is generally considered safe to use at standard doses in patients with mild liver dysfunction. However, if a patient has severe hepatic impairment, the oncologist will monitor liver enzymes (ALT, AST, Bilirubin) closely during treatment.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have underlying organ dysfunction.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (IV); ~77% (SC) |
| Protein Binding | Minimal (it is a protein itself) |
| Half-life | ~28 days (range 1-32 days) |
| Tmax | End of infusion (IV); 3-7 days (SC) |
| Metabolism | Non-specific proteolytic degradation |
| Excretion | Reticuloendothelial system |
Trastuzumab is a large, complex protein with a molecular weight of approximately 148,000 Daltons. Its molecular formula is C6460H9972N1724O2014S44. It consists of two antigen-binding fragments (Fab) linked to a constant region (Fc). The antibody is produced in a mammalian cell culture (Chinese Hamster Ovary cells) and is purified using affinity and ion-exchange chromatography. It is highly soluble in water-based buffers but sensitive to agitation and extreme temperatures, which can cause denaturation (unfolding) of the protein.
Trastuzumab is the prototype of the HER2/neu receptor antagonist class. It is often grouped with other HER2-targeted therapies such as Pertuzumab (which binds to a different part of the HER2 receptor), Ado-trastuzumab emtansine (an antibody-drug conjugate), and Lapatinib (a small-molecule tyrosine kinase inhibitor). Within the EPC classification, it may also be listed as an Endoglycosidase when referring to specific glycoengineered biosimilar versions.